Purpose
|
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin? for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar?. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy.
|
Characteristics
|
Tradename: TEQUIN Source of Compound: synthetic, BMS-206584-01, AM-1155, ethanolamine salt Target: Topoisomerase inhibitor Receptor: Topoisomerase IV Status: USAN, INN
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
98?%
|
Formula
|
C19H22FN3O4
|
Solubility
|
Water: 60 mg/mL (at pH 4)
|